0.899  -0.251 (-21.83%)		12-08 16:00
Open: 1.15 High: 1.15 Volume: 919,406		Pre. Close: 1.15 Low: 0.8921 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	2.21	1-year :	3.53
Resists	First :	1.89	Second :	3.02
Pivot price	0.47
Supports	First :	0.05	Second :	0.04
MAs	MA(5) :	1.28	MA(20) :	0.38
	MA(100) :	0.18	MA(250) :	1.04
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	45.1	D(3) :	55.3
RSI	RSI(14): 57.9
52-week	High :	25	Low :	0.05

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ZVSA ] has closed below upper band by 35.7%. Bollinger Bands are 1747.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.15 - 1.16	1.16 - 1.16
Low:	0.88 - 0.89	0.89 - 0.89
Close:	0.89 - 0.9	0.9 - 0.91

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Thu, 07 Dec 2023
Healthcare Stocks on the Move Thursday: SLDB, UPC, SYRS, FBIO, ZVSA, WVE, OMER, SERA - InvestorsObserver

Thu, 07 Dec 2023
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate ... - Yahoo Finance

Thu, 07 Dec 2023
Why ZyVersa Therapeutics Shares Are Down 40% - ZyVersa Therapeutics (NASDAQ:ZVSA) - Benzinga

Thu, 07 Dec 2023
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today? - InvestorPlace

Thu, 07 Dec 2023
ZyVersa Therapeutics stock dips on pricing $5.0 million securities offering - Seeking Alpha

Wed, 06 Dec 2023
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	44 (M)
Held by Insiders	3.895e+007 (%)
Held by Institutions	54.4 (%)
Shares Short	2,500 (K)
Shares Short P.Month	0 (K)

EPS	-1.567e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-55.7 %
Return on Equity (ttm)	-2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.55
Qtrly Earnings Growth	-2.3 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	2.3e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.